Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Status:
Completed
Trial end date:
2017-10-05
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn about the safety of giving a stem cell
transplant from a tissue-mismatched donor, followed by cyclophosphamide, to patients with
certain types of blood disorders or blood cancers. Melphalan, thiotepa, and fludarabine will
also be given before the transplant.
Researchers will study the health status of these patients at 3 months after the transplant.